Apatinib was demonstrated activity to targeting vascular endothelial growth factor receptor-2 (VEGFR-2), leading down regulation the proliferation of vessel endothelium and inhibiting tumor angiogenesis. The gene discussed is KDR; the disease is neoplasm.